Ketamine for Depression, PTSD, and Chronic Pain, Explained

Ketamine is one of the few interventions in the last 25 years that fundamentally changed how psychiatry thinks about depression. The story is unusual because the drug isn't new (it's been used as an anesthetic since the 1960s), but its low-dose, subanesthetic use for treatment-resistant depression is an entirely different application of the same molecule.

This guide explains how IV ketamine works at clinical doses, what we use it for, what we don't, and what an infusion course actually looks like.

It's longer than most patient-facing primers on this topic because ketamine sits in an unusual position: well-established for one indication, growing evidence for others, marketed irresponsibly by a meaningful subset of clinics, and surrounded by enough public confusion that getting the story right is worth the page space.

A short history

Ketamine was synthesized in 1962 by Calvin Stevens at Parke-Davis. It was approved by the FDA in 1970 as an anesthetic. Its key clinical advantage as an anesthetic was that it preserved respiratory drive and cardiovascular function, which made it especially useful in field medicine and pediatrics. It's still on the WHO's list of essential medicines for that reason.

The discovery of ketamine's antidepressant effect came later. In 2000, Berman and colleagues published a small study showing rapid antidepressant effects in patients with major depression after a single subanesthetic IV dose. The finding was striking because traditional antidepressants take 4 to 6 weeks to show clinical effect; ketamine produced measurable change within hours.

The 2006 Zarate trial expanded the evidence base. Through the 2010s, multiple academic centers developed structured ketamine clinics, primarily focused on treatment-resistant depression. By 2019, Janssen's esketamine (Spravato, the S-enantiomer of ketamine delivered as a nasal spray) received FDA approval for treatment-resistant depression, marking the first formally approved ketamine-based psychiatric medication.

In parallel, a private-market ketamine clinic infrastructure developed across the country, offering IV ketamine off-label for depression, PTSD, anxiety, and chronic pain. Quality across this space varies considerably. Apex's clinical position sits firmly on the supervised-medical end of that spectrum.

What ketamine is, and isn't, at low doses

At anesthetic doses, ketamine is exactly what you'd expect: a dissociative anesthetic with predictable analgesic and amnestic effects, used in surgery and emergency settings. Dosing for surgical anesthesia runs 1 to 2 mg/kg IV bolus.

At subanesthetic doses (typically 0.5 mg/kg over 40 minutes), it's something different. It doesn't put you under. It produces a brief, controllable dissociative state that lasts about 40 minutes from infusion start, with effects largely resolved 30 to 60 minutes after the drip ends.

The mechanism that matters for depression isn't dissociation. It's what happens at the NMDA receptor in glutamatergic pathways, and the downstream effect on synaptic plasticity and BDNF (brain-derived neurotrophic factor) signaling.

In oversimplified terms: ketamine appears to help the brain form new functional connections in pathways that depression and trauma seem to constrain. Animal studies show rapid increases in dendritic spine density in prefrontal cortex within 24 hours of a ketamine dose, which corresponds nicely with the timing of clinical antidepressant effects in humans. The current dominant theory is that ketamine triggers a brief, controlled glutamate surge that activates AMPA receptors, leading to BDNF release, mTOR pathway activation, and the synaptic remodeling that underlies the antidepressant effect.

The receptor pharmacology is more complex than just "NMDA antagonist" (ketamine also has effects on opioid receptors, sigma receptors, monoaminergic transporters, and nicotinic receptors), and there's active debate in the literature about which specific mechanism is most important for the antidepressant effect. The clinical effect, however, is well-established regardless of which mechanistic model is closest to right.

What the evidence supports

There are three main indications with reasonable evidence:

Treatment-resistant depression. The literature here is substantial and growing. Multiple RCTs, supportive meta-analyses, and the FDA's 2019 approval of esketamine collectively establish that subanesthetic ketamine works in patients who haven't responded to standard antidepressants. The response rate in published studies is typically 50 to 70 percent at the end of an induction course, with the strongest effect in the first 24 to 72 hours and a durable signal at 4 to 6 weeks in responders.

The patient population in these studies typically has major depressive disorder with at least two failed adequate antidepressant trials. The response rate to ketamine in this otherwise-difficult-to-treat population is substantially higher than to a third or fourth conventional antidepressant trial.

Suicidal ideation. Ketamine has a distinct, rapid effect on acute suicidality, often within hours, that's separable from the broader antidepressant effect. This has changed how some emergency departments think about high-risk patients. The 2018 Wilkinson individual-patient-data meta-analysis showed clear reductions in suicidal ideation following single doses of ketamine, with effects emerging within 24 hours and sustained for up to a week in many patients.

PTSD. The 2021 JAMA Psychiatry trial on IV ketamine for chronic PTSD by Feder and colleagues showed durable improvements in symptom scores with a structured course of repeat infusions. The evidence base is younger than for depression, but the signal is real and reproducible across multiple recent trials.

Chronic pain. Subanesthetic ketamine has been used for years in complex regional pain syndrome, neuropathic pain, and refractory chronic pain syndromes. It's not first-line. For patients who have exhausted conventional regimens, it can be a meaningful tool. The pain literature is older than the psychiatric literature; ketamine has been part of pain medicine practice in academic centers since the 1990s.

Other emerging indications (with weaker or smaller evidence bases): treatment-resistant anxiety disorders, postpartum depression, obsessive-compulsive disorder, certain forms of chronic headache. We don't claim ketamine treats all of these; we mention them because the literature exists and patients sometimes ask.

How an infusion course typically runs

A standard induction at Apex looks like:

Six infusions over 2 to 3 weeks. Typical scheduling is twice weekly for three weeks, though we can adjust for patient travel and scheduling needs.

Each infusion is 40 minutes of drug time, plus 20 to 30 minutes of monitoring before and after.

A driver is required. You do not drive yourself home. Plan for someone to pick you up or for a ride service.

Vitals, blood pressure, and cardiac monitoring throughout. Pulse oximetry, blood pressure cuff, continuous monitoring of how you're doing.

A quiet, private room with eyeshades and music. The "set and setting" matters. We use noise-canceling headphones with curated playlists or your own choice of music. Comfortable temperature, dim lighting, minimal stimulation.

A staff member checks on you periodically during the infusion and stays close at hand. You're not alone, but the experience is internally focused.

Post-infusion: 30 to 60 minutes of monitored recovery in the room until the dissociative effects have resolved, your vitals are at baseline, and you're cleared to leave.

Between infusions, we ask you to keep working with your mental-health clinician. We do not replace that relationship. We layer on top of it.

After the induction course, patients who respond typically settle into a maintenance schedule: monthly is most common, with some patients spaced out to every 6 to 12 weeks. Some patients respond to a single induction and don't need formal maintenance for a long time. We figure this out together, in writing, based on your response.

What an infusion actually feels like

This is the question patients most often ask in the consultation, so we'll be specific.

Once the IV is in (a small needle in the back of the hand or the inner elbow, much like a routine blood draw), we start the drip. The full subanesthetic dose runs over 40 minutes.

In the first 5 to 10 minutes, you'll notice a sensation of physical heaviness or pleasant lightness. Some patients describe a feeling like sinking into the chair, others a feeling of floating. Mild tingling in extremities is common.

Between 10 and 25 minutes in, the dissociative state deepens. Patients describe a range of experiences: visual changes (colors more vivid, simple geometric patterns when eyes are closed), a sense of being temporarily separate from the body, slowed perception of time, vivid memories surfacing, sometimes emotional release that feels distant and observed rather than overwhelming.

For most patients, the experience is interesting rather than scary. We've found that patients who arrive nervous often emerge curious. Patients with significant anxiety baseline sometimes find the first infusion harder and the second easier as they know what to expect.

From 25 to 40 minutes, the experience plateaus and then begins to wind down. The drip ends, the dissociative effects fade gradually over 20 to 40 minutes.

You'll feel "back to yourself" within 60 minutes of the drip ending, though slightly tired and emotionally open. Some patients describe a residual sense of clarity or perspective for hours to days after. Others feel relatively neutral immediately after but notice the antidepressant effect emerging over the next 24 to 72 hours.

The experience is not the treatment, exactly. The treatment is what's happening at the receptor and synaptic level during and after the infusion. The dissociative experience is real but not the active ingredient. Patients who hate the dissociative aspect can sometimes get away with lower doses or different routes (Spravato nasal spray). We discuss what's likely to work best for you during the consultation.

Set and setting

A vocabulary borrowed from psychedelic literature, applicable to ketamine therapy: "set" is your mindset going into the session, "setting" is the physical and interpersonal environment.

Both matter. A ketamine session in a sterile, fluorescent, anxiety-producing environment with a stressed clinician overseeing it produces a worse experience and probably a worse outcome than the same dose in a calm, well-prepared environment with attentive staff.

Apex builds the clinical setting with this in mind. The procedure room is comfortable and private. We don't rush. We talk through what to expect before the IV goes in. We're available throughout, without intruding on the internal experience.

For the "set" side: we ask you to come well-rested, fed, and with a general sense of what you'd like to focus on. Not a rigid agenda, just an orientation. Some patients have an intention going in ("I want to think about what's been keeping me stuck"); others just want to be open to whatever surfaces. Either approach works.

Integration

The hours and days after each infusion are when the brain is most plastic, and that's also when therapy, journaling, or a structured integration practice can make the most of the window.

What integration looks like, in practical terms:

A therapy session or call with your mental-health clinician in the day or two following the infusion, while the dissociative experience is fresh and the antidepressant lift is at its strongest.

Journaling about what came up during the session and the days following.

Reduced stress and stimulation in the 24 to 48 hours after. Many patients describe a sense of emotional openness that benefits from quiet rather than from a packed schedule.

Talking through specific insights or memories that surfaced during the session, ideally with your therapist.

Patients who treat the infusions as a one-way pharmacological intervention without integration tend to get short-term benefit that fades. Patients who actively engage with what comes up tend to consolidate the effects more durably.

Strongly recommended: an active mental-health relationship

We strongly recommend that patients in our ketamine program have:

An active relationship with a psychiatrist or psychotherapist.

A plan for what they want to work on between sessions.

Honest conversations about substance use, suicidality, and risk factors before starting.

If you don't already have a mental-health clinician, we can connect you with several we work alongside in the DFW area. The right clinician for ketamine integration work is typically someone with experience in trauma-focused therapy or in working with psychedelic-adjacent treatments.

IV vs intranasal vs IM vs oral

The route matters. Different routes produce different bioavailability, different onset times, and different overall experiences.

IV. Most predictable bioavailability. Easiest to titrate. Standard for clinical ketamine therapy. Requires a clinic visit. What Apex offers.

Intranasal (Spravato). The FDA-approved formulation for treatment-resistant depression. Esketamine, the S-enantiomer of ketamine. Self-administered in clinic under supervision. Some insurance coverage. Slightly different pharmacokinetics than IV racemic ketamine.

Intramuscular. Less common in clinic settings. More variable bioavailability than IV.

Oral and sublingual. Substantially lower bioavailability (around 20 to 25 percent for oral). Used in some at-home programs we don't participate in. The clinical evidence for oral/sublingual ketamine is materially weaker than for IV/IM/intranasal, and the safety profile of unsupervised use is meaningfully different from supervised in-clinic care.

We offer IV ketamine and can discuss whether Spravato (delivered through a partner clinic) might be a better fit for your case depending on indication and insurance.

What we don't do

A few things distinguish a clinical ketamine practice from a recreational or wellness-styled one:

We don't run "ketamine wellness drips" for healthy patients who don't have an indication.

We don't prescribe take-home ketamine. The unsupervised at-home market has produced real harms, including high-profile patient deaths, and we don't participate in it.

We don't sell open-ended packages. You pay for the induction course; maintenance is decided after you respond.

We don't run ketamine in a hotel ballroom or a non-medical setting. The monitoring requirements are real.

We don't use ketamine as a substitute for the psychotherapy or psychiatric care most patients need. We layer onto existing care, we don't replace it.

Who we say no to

The most common reasons we decline or postpone:

Active mania or bipolar disorder in an unstable phase. Ketamine can precipitate mania in vulnerable patients. We screen carefully and may decline or coordinate closely with a psychiatrist.

Untreated psychotic disorder. Dissociative experiences in someone whose grip on reality is already tenuous is a bad idea.

Uncontrolled hypertension. Ketamine transiently raises blood pressure. We'll defer until BP is managed.

Severe cardiovascular disease. The cardiac effects of ketamine, while typically mild, are non-trivial for patients with significant existing disease.

Active alcohol or substance use disorder. Ketamine has dissociative properties that can complicate active addiction. We'll often ask patients to address the substance use first, with a clear path back to ketamine consideration afterward.

Pregnancy. Standard exclusion.

A primary mental-health clinician who isn't engaged, when the indication is psychiatric. Ketamine without integration support tends to underperform and isn't worth your money.

When we say no, we explain why and recommend the next step. Sometimes that's getting your hypertension or substance use stabilized first; sometimes it's a different therapeutic direction.

What about Spravato?

Spravato (esketamine nasal spray) is the FDA-approved formulation for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. It's administered in a clinic setting (the FDA REMS program requires supervised administration) and is sometimes covered by commercial insurance, particularly for patients who have failed standard antidepressants.

Pros: FDA-approved, sometimes covered, slightly different side effect profile (some patients tolerate the nasal spray better than IV).

Cons: Less predictable bioavailability than IV, ongoing dosing schedule per FDA labeling, slightly higher per-dose cost without insurance coverage.

If Spravato might be a better fit for your case and your insurance, we'll point you toward clinics that administer it. We do not currently administer Spravato directly, but we maintain referral relationships with clinicians who do.

Cost

Ketamine pricing is quoted per protocol after consultation. Insurance generally does not cover IV ketamine; Spravato sometimes has commercial coverage if you've failed two antidepressants. We're happy to discuss whether the nasal-spray option might be a better fit for your situation, including from a coverage standpoint.

Typical IV ketamine course pricing in the DFW market:

• Single infusion: $400 to $600 depending on clinic.
• Six-infusion induction course: $2,400 to $3,600.
• Maintenance infusions: typical single-dose pricing, scheduled as needed.

We publish our specific pricing during the consultation, with full transparency on what's included.

The honest summary

Ketamine is not a cure for depression, PTSD, or chronic pain. It is, for the right patient, one of the most consistently effective interventions modern medicine has produced for treatment-resistant cases. It works inside a system, not as a magic bullet, and it doesn't work for everyone.

For patients with treatment-resistant depression specifically, the response rate is high enough and the safety profile favorable enough that it deserves consideration in the algorithm, after standard antidepressant trials but before more invasive options.

If you're considering ketamine therapy, the right next step is a workup that figures out whether you're a candidate and whether the structured course is likely to help. Request a consultation or call (972) 768-2328 and we'll walk through it.

A short note from Dr. Abdullah

Ketamine therapy is a place where the gap between what's possible at a good clinic and what's possible at a sloppy clinic is unusually wide. The drug is powerful. The clinical setting matters. The integration matters. The patient selection matters. Done well, it's one of the most rewarding interventions I offer. Done poorly, it can make patients worse. If you're shopping the DFW market for ketamine care, ask the questions you'd ask of any regenerative or behavioral health clinic: who is supervising, what's their training, how is the protocol designed, what does success and failure look like, and what happens if you're not responding. We're happy to be one of the clinics you compare.